Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has decided on the early termination and voluntary withdrawal of its Phase 3 clinical trial plan in Europe for CT-P51, a biosimilar to Keytruda (an immuno-oncology drug). This stems from an adjustment in clinical and regulatory approval strategy following changes in global regulatory trends, while Phase 3 trials in non-EU participating countries will continue.
📊 [Summary of Key Disclosure Content & Major Figures]
- Decision Date: July 14, 2026 (Local Time)
- Regulatory Authority: European Medicines Agency (EMA)
[Clinical Trial Details]
- Trial Title: A Double-Blind, Randomized, Active-Controlled, Phase 3 Clinical Trial to Compare the Efficacy and Safety of CT-P51 versus Keytruda in Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Development Phase: Global Phase 3 Clinical Trial
- Target Indication: Non-Small Cell Lung Cancer (NSCLC)
- Timeline Summary: Application Date August 22, 2024 ➔ Approval Date December 12, 2024 ➔ Early Termination Date July 14, 2026
[Reason for Early Termination & Voluntary Withdrawal]
- Revision of clinical and regulatory strategy toward reducing subject sample size in response to changing global regulatory environments
- Following the completion of patient recruitment, EU member countries were removed from participating sites, eliminating the necessity to maintain the European trial protocol and leading to early termination and voluntary withdrawal
[Future Plans]
- Continuation of the global Phase 3 clinical trial in non-EU participating countries to evaluate and compare efficacy and safety against Keytruda
[Related Prior Filings]
- 2024-08-23: Application for Phase 3 Clinical Trial Plan (Part 1 & 2) of CT-P51 (Keytruda Biosimilar) in Europe
- 2024-12-13: Approval of Phase 3 Clinical Trial Plan (Part 1 & 2) of CT-P51 (Keytruda Biosimilar) in Europe
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Phase 3 Trial Progress in Non-EU Participating Countries and Implementation of Revised Strategy
This disclosure pertains to the early termination and voluntary withdrawal of the European EMA Phase 3 trial following an adjustment in regulatory strategy. Verifying the ongoing progress of the Phase 3 clinical trial in remaining non-EU participating countries and confirming that necessary clinical data is collected under the modified strategy is essential for understanding the overall development pathway of this pipeline. Relevant updates can be verified in future regulatory disclosures, annual business reports, or quarterly and half-yearly reports.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official regulatory data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided strictly for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
